Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia.

Autor:	Ebian HF; Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Abdelnabi AM; Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Abdelazem AS; Medical Biochemistry Department, Faculty of Medicine, Suez University, Suez, Egypt., Khamis T; Pharmacology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt., Fawzy HM; Public Health and Community Medicine Department, Faculty of Medicine, Zagazig University Zagazig, Egypt., Hussein S; Medical Biochemistry& Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Jazyk:	angličtina
Zdroj:	Leukemia research reports [Leuk Res Rep] 2022 May 09; Vol. 17, pp. 100321. Date of Electronic Publication: 2022 May 09 (Print Publication: 2022).
DOI:	10.1016/j.lrr.2022.100321
Abstrakt:	Background: CD26 is expressed in all chronic myeloid leukemia (CML) patients. This study investigated the role of CD26 + LSCs in diagnosis and follow up of CML patients. Method: Flow cytometry was performed to evaluate CD26 + LSC in peripheral blood (PB) in CML patients. BCR-ABL1 transcript level measurement was performed using standard qRT-PCR technique. Results: CD26 + LSCs were significantly correlated with BCR-ABL1 transcript level at diagnosis and after three months of treatment. CD26+ LSCs also were significantly associated with the risk score after 12 months of treatment. Conclusion: CD26+ LSCs can be a useful marker in diagnosis and follow up of patients with CML. Competing Interests: The authors report no conflict of interest. (© 2022 The Authors. Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu